<DOC>
	<DOCNO>NCT00303797</DOCNO>
	<brief_summary>This phase I trial study side effect best dose sorafenib bortezomib treat patient advanced cancer . Sorafenib bortezomib may stop growth cancer cell block enzymes need cell growth . Sorafenib may also stop growth cancer cell block blood flow cancer</brief_summary>
	<brief_title>Sorafenib Bortezomib Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) sorafenib bortezomib patient advanced malignancy . II . To describe toxicity associate combination sorafenib bortezomib . III . To evaluate therapeutic antitumor activity combination sorafenib bortezomib . IV . To evaluate effect sorafenib disposition bortezomib . OUTLINE : This dose-escalation study . Patients assign 1 2 group accord disease type . GROUP I ( solid tumors-dose-escalation group ) : Patients receive oral sorafenib twice daily day 1-21 bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sorafenib bortezomib MTD determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . GROUP II ( multiple myeloma chronic lymphocytic leukemia-maximum tolerate dose [ MTD ] group ) : Patients receive oral sorafenib MTD twice daily day 3-21 course 1 day 1-21 subsequent course . Patients also receive bortezomib IV 3-5 second MTD day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Diagnosis 1 follow : Cytologically histologically proven unresectable solid tumor curative treatment option exist ( group I doseescalation phase ) Multiple myeloma chronic lymphocytic leukemia require treatment ( group II maximum tolerate dose phase ) Failed ≥ 1 prior regimen Nonsecretory myeloma allow No known standard therapy potentially curative definitely capable extend life expectancy exist Tumor amenable serial sampling ( group II ) ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 9 g/dL Platelet count ≥ 100,000/mm^3 ( 75,000/mm^3 patient multiple myeloma [ group II ] ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 3 time ULN ( 5 time ULN liver involvement ) Creatinine ≤ 1.5 time ULN ( 2.5 time ULN patient multiple myeloma [ group II ] ) Life expectancy ≥ 12 week No uncontrolled infection No New York Heart Association class III IV heart disease No uncontrolled hypertension , labile hypertension , history poor compliance antihypertensive medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No sensory peripheral neuropathy etiology &gt; grade 1 neuropathic pain etiology No active HIV infection require therapy No inability swallow would preclude use oral medication No evidence bleed diathesis Medically capable willing provide biologic specimen require ( mandatory patient group II ) Priorbortezomib allow More 3 week since prior chemotherapy ( 6 week mitomycin C nitrosoureas ) recover More 4 week since prior immunotherapy biologic therapy More 2 week since prior steroid therapy ( group II ) No prior antivascular endothelial growth factor therapy More 4 week since prior fullfield radiotherapy ( 2 week limitedfield radiotherapy ) No prior radiation &gt; 25 % bone marrow More 4 week since major surgery ( e.g. , laparotomy ) ( 2 week minor surgery ) Insertion vascular access device consider major minor surgery No concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational No concurrent prophylactic colonystimulating factor No concurrent therapeutic anticoagulation Concurrent prophylactic anticoagulation ( i.e. , lowdose warfarin ) venous arterial access device allow provided requirement PT , INR , PTT meet No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John 's Wort ) No concurrent participation study involve pharmacologic agent ( e.g. , drug , biologics , immunotherapy , gene therapy ) , either symptom control , therapeutic intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>